Dismissing an appeal in Commissioner of Central Excise, Mumbai IV v M/s Ciens Laboratories, Mumbai, & Anr, the Supreme Court recently held that “a product that is used mainly in curing or treating ailments or diseases and contains curative ingredients even in small quantities is to be branded as a medicament”.
As such, the court held that two tribunals – the Customs, Excise and Gold (Control) Appellate Tribunal, and the Customs, Excise and Service Tax Appellate Tribunal – had rightly held that a cream used for the cure of certain skin diseases, produced by Ciens Laboratories, is a medicament and was to be taxed accordingly.
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.
你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章,欢迎成为我们的订阅会员成为我们的订阅会员。
The update of court judgments is compiled by Bhasin & Co, Advocates, a corporate law firm based in New Delhi. The authors can be contacted at lbhasin@bhasinco.in or lbhasin@gmail.com. Readers should not act on the basis of this information without seeking professional legal advice.